Boone Capital Management
Latest statistics and disclosures from Boone Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are UNM, CI, MOH, ENOV, BAX, and represent 41.08% of Boone Capital Management's stock portfolio.
- Added to shares of these 10 stocks: VKTX (+$26M), TARS (+$22M), CI (+$15M), BERY (+$13M), BIO (+$13M), HCSG (+$12M), AMPH (+$9.1M), MLAB (+$7.6M), MOH (+$7.2M), OFIX (+$6.9M).
- Started 3 new stock positions in TARS, VKTX, HCSG.
- Reduced shares in these 7 stocks: AMGN (-$29M), CVS (-$29M), BBIO (-$18M), DHR (-$11M), VTRS (-$9.3M), QTRX (-$5.6M), MIRM.
- Sold out of its positions in AMGN, BBIO, CVS.
- Boone Capital Management was a net buyer of stock by $45M.
- Boone Capital Management has $494M in assets under management (AUM), dropping by 15.40%.
- Central Index Key (CIK): 0001882053
Tip: Access up to 7 years of quarterly data
Positions held by Boone Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boone Capital Management
Boone Capital Management holds 21 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Unum (UNM) | 11.1 | $55M | +6% | 1.0M | 53.66 |
|
| Cigna Corp (CI) | 9.7 | $48M | +47% | 132k | 363.19 |
|
| Molina Healthcare (MOH) | 7.1 | $35M | +25% | 86k | 410.83 |
|
| Colfax Corp (ENOV) | 7.1 | $35M | 563k | 62.45 |
|
|
| Baxter International (BAX) | 6.0 | $30M | +27% | 698k | 42.74 |
|
| Globus Med Cl A (GMED) | 5.7 | $28M | 530k | 53.64 |
|
|
| Berry Plastics (BERY) | 5.5 | $27M | +94% | 450k | 60.48 |
|
| Amphastar Pharmaceuticals (AMPH) | 5.4 | $27M | +51% | 607k | 43.91 |
|
| Viking Therapeutics (VKTX) | 5.1 | $26M | NEW | 311k | 82.00 |
|
| Bio Rad Labs Cl A (BIO) | 5.1 | $25M | +102% | 72k | 345.87 |
|
| Ideaya Biosciences (IDYA) | 4.7 | $23M | 532k | 43.88 |
|
|
| Tarsus Pharmaceuticals (TARS) | 4.5 | $22M | NEW | 609k | 36.35 |
|
| Danaher Corporation (DHR) | 3.3 | $16M | -39% | 66k | 249.72 |
|
| Mesa Laboratories (MLAB) | 3.0 | $15M | +108% | 133k | 109.73 |
|
| Orthofix Medical (OFIX) | 2.9 | $14M | +94% | 975k | 14.52 |
|
| Viatris (VTRS) | 2.7 | $14M | -40% | 1.1M | 11.94 |
|
| Xenon Pharmaceuticals (XENE) | 2.5 | $13M | +14% | 291k | 43.05 |
|
| Healthcare Services (HCSG) | 2.3 | $12M | NEW | 927k | 12.48 |
|
| Mirum Pharmaceuticals (MIRM) | 2.3 | $11M | -7% | 452k | 25.12 |
|
| Pennant Group (PNTG) | 2.2 | $11M | +71% | 564k | 19.63 |
|
| Quanterix Ord (QTRX) | 1.6 | $7.8M | -41% | 330k | 23.56 |
|
Past Filings by Boone Capital Management
SEC 13F filings are viewable for Boone Capital Management going back to 2022
- Boone Capital Management 2024 Q1 filed May 15, 2024
- Boone Capital Management 2023 Q4 filed Feb. 14, 2024
- Boone Capital Management 2023 Q3 filed Nov. 14, 2023
- Boone Capital Management 2023 Q2 filed Aug. 14, 2023
- Boone Capital Management 2023 Q1 filed May 15, 2023
- Boone Capital Management 2022 Q4 filed Feb. 14, 2023